Barnhill R L, Castresana J S, Rubio M P, Martin M T, Idoate M, Vazquez J J, Thor A D
Department of Pathology (Dermatopathology), Brigham and Women's Hospital, Boston, Massachusetts.
Mod Pathol. 1994 Jun;7(5):533-5.
Recent studies on the role of the p53 gene in human melanoma have largely been contradictory. To further assess p53 expression in melanoma, we have studied p53 immunoreactivity in 87 cases of primary, recurrent, and metastatic melanoma. Routine immunostaining was performed on paraffin sections with the monoclonal antibody PAb1801 and a streptavidin-biotin method. All specimens were blindly and independently assessed by two observers for number of melanoma cells with granular nuclear staining. Seven melanomas (8%) exhibited from 1 to 50% positive cells and another eight cases (9%) showed p53 immunoreactivity in < 1% of cells. All of the melanomas found to be positive for p53 with one exception (< 1.50 mm) were either thicker than 1.50 mm, recurrent, or metastatic. We conclude that these findings provide little evidence for significant p53 alteration in the initiation and development of melanoma.
最近关于p53基因在人类黑色素瘤中作用的研究大多相互矛盾。为了进一步评估黑色素瘤中p53的表达情况，我们研究了87例原发性、复发性和转移性黑色素瘤的p53免疫反应性。用单克隆抗体PAb1801和链霉亲和素-生物素法对石蜡切片进行常规免疫染色。两位观察者对所有标本进行盲法独立评估，统计细胞核呈颗粒状染色的黑色素瘤细胞数量。7例黑色素瘤（8%）有1%至50%的阳性细胞，另外8例（9%）的p53免疫反应性细胞少于1%。除1例（<1.50 mm）外，所有p53呈阳性的黑色素瘤均厚度超过1.50 mm、为复发性或转移性。我们得出结论，这些发现几乎没有证据表明p53在黑色素瘤的发生和发展过程中有显著改变。
